The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial
about
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial
description
article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у 2018
@uk
name
The TLR-4 agonist adjuvant, GL ...... vaccine: first-in-human trial
@en
The TLR-4 agonist adjuvant, GL ...... vaccine: first-in-human trial
@nl
type
label
The TLR-4 agonist adjuvant, GL ...... vaccine: first-in-human trial
@en
The TLR-4 agonist adjuvant, GL ...... vaccine: first-in-human trial
@nl
prefLabel
The TLR-4 agonist adjuvant, GL ...... vaccine: first-in-human trial
@en
The TLR-4 agonist adjuvant, GL ...... vaccine: first-in-human trial
@nl
P2093
P2860
P50
P1433
P1476
The TLR-4 agonist adjuvant, GL ...... vaccine: first-in-human trial
@en
P2093
Ann Ginsberg
Anna Marie Beckmann
David Hokey
Franco M Piazza
Galit Alter
Julie Vergara
Lenette Lu
Margaret Ann Snowden
Rhea N Coler
Robert Walker
P2860
P2888
P356
10.1038/S41541-018-0057-5
P407
P577
2018-01-01T00:00:00Z